Polymerase inhibitor
Showing 1 - 25 of 8,302
Acute Myeloid Leukemia Trial in Baltimore (Decitabine, talazoparib)
Active, not recruiting
- Acute Myeloid Leukemia
-
Baltimore, MarylandUniversity of Maryland Greenebaum Comprehensive Cancer Center
May 31, 2022
Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))
Active, not recruiting
- Ovarian Neoplasms
- +2 more
- KU-0059436 (AZD2281)(PARP inhibitor)
-
Brussels, Belgium
- +4 more
Dec 19, 2022
HRD and Resistance to PAPPi in EOC Patients
Recruiting
- Epithelial Ovarian Cancer
- +6 more
- Testing of homologous recombination deficiency
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial (Biopsy, Diagnostic Imaging, Novobiocin Sodium)
Not yet recruiting
- Metastatic Malignant Solid Neoplasm
- Unresectable Malignant Solid Neoplasm
- Biopsy
- +2 more
- (no location specified)
Jan 14, 2023
Advanced Solid Tumors Trial in United States (KSQ-4279, KSQ-4279 will be combined in separate cohorts, including combination
Recruiting
- Advanced Solid Tumors
- KSQ-4279
- KSQ-4279 will be combined in separate cohorts, including combination with an oral PARPi (poly adenosine diphosphate-ribose polymerase inhibitor)
-
Boston, Massachusetts
- +4 more
Apr 5, 2022
Advanced Solid Tumor, Metastatic Solid Tumor Trial (ART6043, Olaparib, Talazoparib)
Not yet recruiting
- Advanced Solid Tumor
- Metastatic Solid Tumor
- ART6043
- +2 more
- (no location specified)
Jun 1, 2023
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib
Not yet recruiting
- Ovarian Cancer
- +4 more
- Fluzoparib Capsules
- Bevacizumab
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Cetntre
Sep 25, 2023
NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- EGF-R Positive Non-Small Cell Lung Cancer
- Parimparib
- +2 more
-
Wuxi, Jiangsu, ChinaAffiliated Hospital of Jiangnan University
Jan 30, 2023
Homologous Recombination Deficiency in Chinese Ovarian Cancer
Not yet recruiting
- Ovarian Cancer
- +2 more
- PARP inhibitor
-
Nanjing, Jiangsu, ChinaXiaoxiang Chen, MD,PhD
Sep 4, 2021
Covid19, SARS-CoV Infection Trial in Seattle (Zinc Picolinate, Resveratrol, Zinc Picolinate Placebo)
Terminated
- Covid19
- SARS-CoV Infection
- Zinc Picolinate
- +3 more
-
Seattle, WashingtonSwedish Medical Center
Jul 26, 2022
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer Trial in Baltimore (Olaparib)
Recruiting
- Renal Cell Carcinoma
- +4 more
-
Baltimore, MarylandJohns Hopkins Sidney Kimmel Comprehensive Cancer Center
Mar 14, 2022
Tumors, Breast Tumors Trial in Japan (talazoparib)
Active, not recruiting
- Neoplasms
- Breast Neoplasms
-
Nagoya, Aichi, Japan
- +7 more
Dec 20, 2021
Recurrent Glioma, Recurrent Glioblastoma, Poly ADP Ribose Polymerase (PARP) Inhibitor Trial in Hong Kong (Talazoparib)
Recruiting
- Recurrent Glioma
- +4 more
-
Hong Kong, Hong KongDepartment of Clinical Oncology
Aug 19, 2021
Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal
Recruiting
- Advanced Malignant Solid Neoplasm
- +28 more
- Trifluridine and Tipiracil Hydrochloride
- Talazoparib Tosylate
-
Buffalo, New YorkRoswell Park Cancer Institute
Mar 2, 2022
Breast Tumors, Triple-Negative, Breast Tumor Malignant Female, Radiotherapy Side Effect Trial in Paris (Olaparib, Radiation
Active, not recruiting
- Breast Neoplasms, Triple-Negative
- +2 more
- Olaparib
- Radiation therapy
-
Paris, FranceInstitut Curie
Oct 23, 2020
Metastatic Malignant Solid Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in United States
Active, not recruiting
- Metastatic Malignant Solid Neoplasm
- +4 more
- Laboratory Biomarker Analysis
- +4 more
-
Phoenix, Arizona
- +14 more
Sep 1, 2022
Metastatic Breast Cancer Trial in Herlev, Vejle (PARP inhibitor 2X-121)
Active, not recruiting
- Metastatic Breast Cancer
- PARP inhibitor 2X-121
-
Herlev, Denmark
- +1 more
Feb 1, 2023
Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)
Not yet recruiting
- Ovarian Cancer Recurrent
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Jan 5, 2023
Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)
Not yet recruiting
- Metastatic Solid Tumor
- +4 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 12, 2023